For the 26th prioritisation (March 2016), 12 drugs were filtered out of 224 identified and were sent to prioritisation. Of these, 2 drugs were ranked as "highly relevant" by the expert panel, 9 as "relevant" and 1 as "not relevant". For "highly relevant" drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.